Neuropace Inc cash flow statement
In fiscal 2025, Neuropace Inc's operations generated −$11.0m of cash; it spent $332,000 on capital projects, leaving free cash flow of −$11.3m. It returned $49.5m through buybacks.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −22 | −25 | −37 | −20 | −18 | −11 | −11 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 1 | 4 | 8 | 10 | 10 | 11 | 10 |
| Capital spending | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | −22 | −25 | −37 | −20 | −18 | −11 | −12 |
| Free cash flow after stock pay | −23 | −29 | −46 | −29 | −29 | −22 | −21 |
| Share buybacks | — | — | — | — | 0 | 50 | 0 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −2 | −5 | −7 | −2 | −2 | 1 | −6 | −4 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −2 | −5 | −8 | −2 | −2 | 0 | −6 | −4 |
| Free cash flow after stock pay | −4 | −7 | −10 | −5 | −5 | −2 | −8 | −6 |
Compare with peers
- Ceribell, Inc. cash flow
- Delcath Systems, Inc. cash flow
- Iradimed Corp cash flow
- Xtant Medical Holdings, Inc. cash flow
- Sanara Medtech Inc. cash flow
Head to head: CBLL vs NPCEDCTH vs NPCEIRMD vs NPCE
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies